What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report that Regeneron's shareholders have approved an amendment and restatement of the company's 2000 Long-Term Incentive Plan. This includes an increase in the number of shares available for equity awards and an extension of the Plan's term.

How does the increase in available shares affect existing shareholders?

The increase of 10,000,000 shares means more company stock can be issued as equity compensation. This can lead to dilution of existing shareholders' ownership percentage over time, although it is a common practice to incentivize and retain key employees and executives.

What is the significance of the extended Plan term?

Extending the Plan's term until December 31, 2013, allows the company to continue using equity-based compensation as a tool for attracting, retaining, and motivating employees and executives for a longer period. It provides flexibility for future compensation arrangements.

What does 're-approval for purposes of Section 162(m)' mean for the company?

This re-approval ensures that certain performance-based awards granted under the Plan can qualify for tax deductibility for the company under Section 162(m) of the Internal Revenue Code. This is a significant tax consideration for the company, potentially preserving valuable tax benefits.

REGN 8-K: Leadership Changes

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 17, 2008, to report on a significant shareholder-approved amendment and restatement of its 2000 Long-Term Incentive Plan (the "Plan"). The key change involves increasing the share pool available for equity awards by 10,000,000 shares, bringing the total to 28,500,000 shares. This expansion aims to support future compensation for employees and executives through stock-based incentives. Furthermore, the term of the Plan has been extended to December 31, 2013, providing a longer runway for equity grants. The amendments also incorporate certain stock plan design "best practices" and ensure re-approval for performance-based compensation under Section 162(m) of the Internal Revenue Code. This filing is crucial for investors to understand the company's compensation strategy and its potential impact on share dilution.

Key Highlights

1Shareholders approved an amendment and restatement of the 2000 Long-Term Incentive Plan.
2The maximum number of shares reserved for the Plan increased by 10,000,000 to a total of 28,500,000 shares.
3The term of the Plan has been extended until December 31, 2013.
4The amended Plan includes certain 'best practices' in stock plan design.
5Shareholder approval also re-approved performance goals for Section 162(m) compliance.
6The filing ensures transparency regarding the company's equity compensation strategy.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 17, 2008)

Summary

Key Highlights

Frequently Asked Questions